In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 661 ( 2022-09-07)
Abstract:
A challenge for HIV-1 vaccine development is the need to induce a polyclonal neutralizing antibody (nAb) response in vaccine recipients. Here, Saunders et al. vaccinated rhesus macaques with a stabilized HIV-1 envelope trimer mixed with a Toll-like receptor 7/8 agonist with the goal of eliciting such nAbs. The authors observed that vaccinated macaques developed potent nAbs that targeted multiple sites on the envelope, including the CD4 binding site. This translated into protection against mucosal simian-human immunodeficiency virus challenge in the macaques. These results support further development of this vaccine as a strategy to induce nAbs in humans.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abo5598
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022